LEVOFLOXACIN Drug Patent Profile

Which patents cover Levofloxacin, and when can generic versions of Levofloxacin launch?

Levofloxacin is a drug marketed by Avet Lifesciences, Baxter Hlthcare Corp, Eugia Pharma, Gland, Hospira, Pharmobedient, Rising, Zydus Pharms, Micro Labs Ltd India, Rubicon Research, Sciegen Pharms, Watson Labs Teva, Lannett Co Inc, Novitium Pharma, Apotex Inc, Aurobindo Pharma Ltd, Chartwell Molecular, Chartwell Rx, Dr Reddys Labs Inc, Glenmark Pharms Ltd, Hec Pharm, Hetero Labs Ltd V, Jubilant Generics, Lupin, Macleods Pharms Ltd, Natco Pharma, Orbion Pharms, Sandoz, Teva, Torrent Pharms, Watson Labs Inc, Zydus Lifesciences, Fresenius Kabi Usa, Hikma Farmaceutica, Inforlife, and Knack. and is included in forty-three NDAs.

The generic ingredient in LEVOFLOXACIN is levofloxacin. There are thirty-one drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the levofloxacin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Levofloxacin

A generic version of LEVOFLOXACIN was approved as levofloxacin by RISING on December 20^th, 2010.

Summary for LEVOFLOXACIN

US Patents:	0
Applicants:	36
NDAs:	43
Finished Product Suppliers / Packagers:	38
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	318
Patent Applications:	3,716
Drug Prices:	Drug price information for LEVOFLOXACIN
Drug Sales Revenues:	Drug sales revenues for LEVOFLOXACIN
DailyMed Link:	LEVOFLOXACIN at DailyMed

See drug prices for LEVOFLOXACIN

See drug sales revenues for LEVOFLOXACIN

Recent Clinical Trials for LEVOFLOXACIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Virginia	PHASE3
National Institute of Allergy and Infectious Diseases (NIAID)	PHASE3
Gadjah Mada University	PHASE4

See all LEVOFLOXACIN clinical trials

Medical Subject Heading (MeSH) Categories for LEVOFLOXACIN

Anti-Bacterial Agents

Anti-Infective Agents, Urinary

Cytochrome P-450 CYP1A2 Inhibitors

Topoisomerase II Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for LEVOFLOXACIN

J01MA	Fluoroquinolones
J01M	QUINOLONE ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AE	Fluoroquinolones
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for LEVOFLOXACIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LEVAQUIN	Oral Solution	levofloxacin	25 mg/mL	021721	1	2009-07-30

US Patents and Regulatory Information for LEVOFLOXACIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs Inc	LEVOFLOXACIN	levofloxacin	TABLET;ORAL	201484-002	Nov 22, 2013		DISCN	No	No
Glenmark Pharms Ltd	LEVOFLOXACIN	levofloxacin	TABLET;ORAL	200250-003	Jun 20, 2011	AB	RX	No	No
Chartwell Molecular	LEVOFLOXACIN	levofloxacin	TABLET;ORAL	076890-003	Mar 30, 2012	AB	RX	No	No
Gland	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER	levofloxacin	INJECTABLE;INJECTION	206908-001	Dec 30, 2020	AP	RX	No	No
Jubilant Generics	LEVOFLOXACIN	levofloxacin	TABLET;ORAL	203613-002	Jun 19, 2015		DISCN	No	No

EU/EMA Drug Approvals for LEVOFLOXACIN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Chiesi Farmaceutici S.p.A	Quinsair	levofloxacin	EMEA/H/C/002789Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.Consideration should be given to official guidance on the appropriate use of antibacterial agents.	Authorised	no	no	no	2015-03-25

Market Dynamics and Financial Trajectory for Levofloxacin

Last updated: February 19, 2026

Levofloxacin remains a prominent fluoroquinolone antibiotic with substantial global sales driven by its broad-spectrum activity against respiratory and urinary tract infections. The market landscape is influenced by patent expirations, emergence of resistance, regulatory environment, and shifts in prescribing practices. Financial trends reflect ongoing demand in mature markets and competitive pressures from generic manufacturers.

Market Size and Growth Trends

The global levofloxacin market was valued at approximately USD 2.9 billion in 2021. Compound annual growth rate (CAGR) is estimated at 4-6% from 2022 to 2027, driven by:

• Prevalence of respiratory infections such as pneumonia and bronchitis.
• Increasing antibiotic prescriptions in emerging economies.
• New formulations aimed at improving patient compliance.

Despite the pandemic, sales continued to expand, though at a slower pace than pre-2020 levels.

Key Market Drivers

Expanded Indications

Levofloxacin is prescribed for respiratory tract infections, urinary tract infections, skin infections, and anthrax prophylaxis. Its efficacy against resistant strains sustains demand.

Rising Antibiotic Resistance

Resistance to fluoroquinolones poses a challenge; certain bacterial strains are developing reduced susceptibility, which may limit clinical use and impact revenue.

Patent Expirations and Generics

The initial patent protection of branded levofloxacin, held by Daiichi Sankyo, expired in many markets around 2011, paving the way for generic versions that account for over 70% of global sales. Price competition has reduced profit margins for new formulations and branded versions.

Regulatory and Safety Concerns

Post-marketing safety warnings about potential adverse effects—tendinitis, tendon rupture, QT prolongation—have prompted tighter prescribing guidelines, influencing sales volume.

Competitive Landscape

Company	Market Share (2022)	Key Products	Notes
Sandoz (Novartis)	38%	Generic levofloxacin tablets	Dominates in generics
Teva Pharmaceuticals	25%	Generic formulations	Focused on cost-competitive markets
Daiichi Sankyo (Brand)	15%	Levaquin (brand), marketed mainly in the US	Declining volume due to patent loss
Others	22%	Smaller regional players	Varying market shares

Pricing Dynamics

Prices for levofloxacin have decreased over the past decade, with generics generally costing 50-70% less than branded versions. Recent safety concerns have created variability; some markets see seasonal price fluctuations influenced by regulatory restrictions.

Regulatory Environment and Policy Impact

Regulatory agencies in the US (FDA), EU (EMA), and emerging markets impose restrictions on fluoroquinolone use. The FDA issued safety labeling changes in 2016, impacting prescribing rates domestically. These policies reduce volume growth from certain applications but may push innovation into new formulations with improved safety profiles.

Innovation and Pipeline

Limited recent pipeline development by major players indicates a focus on optimizing existing formulations. No significant pipeline candidates have received regulatory approval in the last two years, reflecting a plateau in innovation specific to levofloxacin.

In contrast, newer antibiotics with broader spectra and improved safety are gradually replacing levofloxacin in some indications, especially in resistant infections.

Financial Outlook and Projections

Year	Estimated Global Sales (USD billion)	Notes
2022	2.9	Baseline established
2023	3.0	Slight growth driven by emerging markets
2025	3.3 – 3.5	Expected plateau due to market saturation and resistance issues
2030	2.8 – 3.0	Potential decline if safety concerns limit use, or if new drugs replace levofloxacin

Risks and Opportunities

• Risks: Resistance development, safety concerns, regulatory restrictions, and commoditization of generics. These factors can suppress sales growth or cause declines.
• Opportunities: Development of formulations with improved safety profiles, new delivery mechanisms, and expansion into emerging markets with increasing antibiotic use.

Conclusion

Levofloxacin's market remains sizable but faces declining profitability due to patent expirations and increasing regulatory and safety hurdles. While demand persists in certain indications, the overall trajectory suggests stabilization or slight decline in the coming decade unless innovation or new indications emerge.

Key Takeaways

• The global market is valued at approximately USD 2.9 billion in 2022, with sustained demand in respiratory and urinary infections.
• Generics dominate sales, accounting for over 70% of revenue, driving pricing pressures.
• Safety warnings and resistance threaten future growth, likely constraining market expansion.
• Limited pipeline development points to a market plateau, with existing products maintaining most sales.
• Emerging markets offer growth potential, contingent on regulatory and safety landscape adaptations.

FAQs

1. What is the primary driver of levofloxacin sales globally?
   Its broad-spectrum activity against respiratory and urinary tract infections sustains demand, especially in regions with rising infection rates.

2. How do patent expirations impact levofloxacin's market?
   Patents expired around 2011 in many jurisdictions, enabling generic manufacturers to enter the market and reducing prices.

3. What safety concerns influence levofloxacin prescribing?
   Risks of tendinitis, tendon rupture, and QT prolongation have led to guideline restrictions, especially in higher-risk populations.

4. Is there ongoing innovation for levofloxacin?
   No significant new formulations or indications have been approved recently; focus has shifted to competitors with improved safety profiles.

5. What is the outlook for levofloxacin in emerging markets?
   Growth is expected due to increasing infection prevalence and demand for affordable antibiotics, though regulatory challenges remain.

References

1. Statista. (2022). Global antibiotic market size.
2. Daiichi Sankyo. (2021). Levofloxacin product information.
3. FDA. (2016). Safety labeling updates for fluoroquinolone antibiotics.
4. MarketsandMarkets. (2022). Antibiotics market growth forecasts.
5. WHO. (2021). Global antimicrobial resistance surveillance reports.